Myocardial viability and survival in ischemic left ventricular dysfunction.
Bonow RO,
Maurer G,
Lee KL,
Holly TA,
Binkley PF,
Desvigne-Nickens P,
Drozdz J,
Farsky PS,
Feldman AM,
Doenst T,
Michler RE,
Berman DS,
Nicolau JC,
Pellikka PA,
Wrobel K,
Alotti N,
Asch FM,
Favaloro LE,
She L,
Velazquez EJ,
Jones RH,
Panza JA;
STICH Trial Investigators.
Cherniavsky A, Marchenko A, Romanov A, Wos S, Deja M, Golba K, Malinowski M, Gradinac S, Kosevic D, Vukovic M, Djokovic L, Krzeminska-Pakula M, Jaszewski R, Drozdz J, Chrzanowski L, Rajda M, Ali I, Howlett J, MacFarlane M, Jain A, Shah H, Rakshak D, Saxena A, Zembala M, Przybylski R, Kukulski T, Wasilewski J, Wiechowski S, Brykczynski M, Kurowski M, Mokrzycki K, Sadowski J, Kapelak B, Sobczyk D, Plicner C, Wrobel K, Piegas L, Paulista P, Farsky P, Veiga Kantorowitz C, Sadowski Z, Juraszynski Z, Szwed H, Dabrowski R, Rogowski J, Pawlaczyk R, Rynkiewicz A, Betlejewski P, Siepe M, Geibel-Zehender A, Cuerten C, Higgins R, Crestanello J, Binkley P, Jones D, Sun B, Velazquez E, Smith P, Milano C, Adams P, Hill J, Beaver T, Leach D, Airan B, Das S, Yii M, Prior D, Mack J, Rao V, Iwanochko R, Renton J, Panchavinnin P, Phuangkaew N, Bochenek A, Krejca M, Trusz-Gluza M, Wita K, Ferrazzi P, Gavazzi A, Senni M, Natarajan S, Padmanabhan C, Racine N, Bouchard D, Ducharme A, Brown H, Alotti N, Lupkovics G, Kumar S, Agarwal S, Sinha N, Rai H, Andersson B, Janssen A, Lamy A, Demers C, Rizzo T, Doenst T, Garbade J, Thiele H, Richter M, Petrie M, Murday A, Shaw M, Raju K, Mannam G, Reddy G, Rao K, Nicolau J, Stolf N, Vieira A, Chua YL, Lim CH, Kwok B, Gan YC, Cleland J, Cale A, Thackray S, Lammiman M, Michler R, Swayze R, Maurer G, Grimm M, Lang I, Adlbrecht C, Daly R, Rodeheffer R, Nelson S, Larbalestier R, Wang X, Haddad H, Hendry P, Donaldson J, Menicanti L, Di Donato M, Castelvecchio S, Sirvydis V, Voluckiene E, Di Benedetto G, Attisano T, Favaloro R, Favaloro L, Diez M, Riccitelli M, Picone V, Koslowski P, Gaito M, Al-mohammad A, Braidley P, Steele H, Nawarawong W, Woragidpoonpol S, Kuanprasert S, Mekara W, Kon N, Hammon J, Wells G, Tilley W, Drazner M, DiMaio M, Peschka S, De Pasquale C, Knight J, Aylward P, Thomas C, Gullestad L, Sorensen G, Kaul U, Gupta R, Schmedtje J Jr, Arnold S, Wilson V, Grayburn P, Hamman B, Hebeler R, Aston S, Birjiniuk V, Harrington M, Dupree C, Sheridan B, Schuler C, Helou J, Denis I, Bigalli D, Gutierrez F, Russo N, Batlle C, White H, Alison P, Stewart R, Borthwick L, Philippides G, Shemin R, Fitzgerald C, Dagenais F, Dussault G, Kamath P, Busmann C, Ferrari G, Botto M, Horkay F, Hartyanszky I, Bartha E, Simor T, Papp L, Toth L, Varga-Szemes A, Horkay F, Szekely L, Keltai M, Edes I, Szathmarine V, Yakub M, Sarip S, Maitland A, Isaac D, Holland M, Bogats G, Csepregi L, Maia L, Soares M, Mouco O, Souza A, da Rocha AC, Brito JR, Pitella FM, Camara AG, Horowitz J, Knight J, Rose J, McRae R Jr, Geiss D, Clemson B, Pierson M, Kron I, Kern J, Bergin J, Phillips J, Rich J, Herre J, Pine L, Chin D, Spyt T, Logtens E, Amuchastegui L, Bracco D, Ruengsakulrach P, Pitiguagool V, Sukhum P, Srinualta D, Hayward C, Herrera C, Zimmermann R, Patterson G, Stephens W, Dignan R, French J, Sequalino N, Vaishnav S, Panda R, Chavan A, Benetis R, Jankauskiene L, Kalil R, Nesralla I, Santos M, de Moraes M, Friedrich I, Buerke M, Paraforos A, Konda S, Leone C, Murphy E, Ravichandran P, Avalos K, Hetzer R, Knosalla C, Hoffmann K, Landolfo K, Landolfo C, Park M, Chiariello L, Nardi P, Stapleton D, Hoey K, Hasaniya N, Wang N, Bijou R, Naka Y, Ascheim D, Mikati I, Arnold M, McKenzie N, Smith J, Gheorghiade M, Fullerton D, Roberts L, Carson P, Dupree C, Miller A, Pina I, Selzman C, Wertheimer J, Goldstein S, Cohn F, Hlatky M, Kennedy K, Rankin S, Robbins R, Zaret B, Rouleau J, Barfield T, Desvigne-Nickens P, Jones R, Lee K, Michler R, O'Connor C, Oh J, Rankin G, Sopko G, Velazquez E, Hill J, Bonow R, Desvigne-Nickens P, Doenst T, Jones R, Lee K, Michler R, Oh J, Panza J, Rouleau J, Sadowski Z, Sopko G, Velazquez E, White H, Pohost G, Agarwal S, Apte P, Doyle M, Forder J, Ocon M, Pai R, Reddy V, Santos N, Tripathi R, Varadarajan P, Oh J, Pellikka P, Miller F Jr, Lin G, Borgeson D, Ommen S, Casaclang-Verzosa G, Miller D, Springer R, Blahnik F, Manahan B, Welper J, Wiste H, Mark D, Anstrom K, Baloch K, Burnette A, Cowper P, Davidson-Ray N, Drew L, Harding T, Hunt V, Knight D, Patterson A, Redick T, Sanderford B, Feldman A, Bristow M, Chan T, Maisel A, Mann D, McNamara D, Bonow R, Holly T, Berman D, Leonard S, Helmer D, Woods M, Panza J, McNulty M, Asch F, Rumsey M, Bieganski S, Grayburn P, Aston S, Roberts B, Handschumacher M, Jones R, Velazquez E, O'Connor C, Rankin G, Barfield T, McCormick A, Albright J, Dandridge R, Rittenhouse L, Wagstaff D, Williams M, Bailey D, Glover D, Parrish L, Wakeley N, Jackson V, Nicholson B, Lee K, She L, McDaniel A, Al-Khalidi H, Greene D, Moore V.
Source
Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, 645 N. Michigan Ave., Suite 1006, Chicago, IL 60611, USA. r-bonow@northwestern.edu
Abstract
BACKGROUND:
The assessment of myocardial viability has been used to identify patients with coronary artery disease and left ventricular dysfunction in whom coronary-artery bypass grafting (CABG) will provide a survival benefit. However, the efficacy of this approach is uncertain.
METHODS:
In a substudy of patients with coronary artery disease and left ventricular dysfunction who were enrolled in a randomized trial of medical therapy with or without CABG, we used single-photon-emission computed tomography (SPECT), dobutamine echocardiography, or both to assess myocardial viability on the basis of prespecified thresholds.
RESULTS:
Among the 1212 patients enrolled in the randomized trial, 601 underwent assessment of myocardial viability. Of these patients, we randomly assigned 298 to receive medical therapy plus CABG and 303 to receive medical therapy alone. A total of 178 of 487 patients with viable myocardium (37%) and 58 of 114 patients without viable myocardium (51%) died (hazard ratio for death among patients with viable myocardium, 0.64; 95% confidence interval [CI], 0.48 to 0.86; P=0.003). However, after adjustment for other baseline variables, this association with mortality was not significant (P=0.21). There was no significant interaction between viability status and treatment assignment with respect to mortality (P=0.53).
CONCLUSIONS:
The presence of viable myocardium was associated with a greater likelihood of survival in patients with coronary artery disease and left ventricular dysfunction, but this relationship was not significant after adjustment for other baseline variables. The assessment of myocardial viability did not identify patients with a differential survival benefit from CABG, as compared with medical therapy alone. (Funded by the National Heart, Lung, and Blood Institute; STICH ClinicalTrials.gov number, NCT00023595.).
- PMID:
- 21463153
- [PubMed - indexed for MEDLINE]
- PMCID:
- PMC3290901
Free PMC ArticleFigure 1Kaplan–Meier Analysis of the Probability of Death, According to Myocardial Viability Status
The comparison that is shown has not been adjusted for other prognostic baseline variables. After adjustment for such variables on multivariable analysis, the between-group difference was not significant (P = 0.21).
N Engl J Med. N Engl J Med;364(17):1617-1625.
Figure 2Kaplan–Meier Analysis of the Probability of Death According to Myocardial-Viability Status and Treatment
At 5 years in the intention-to-treat analysis, the rates of death for patients without myocardial viability were 41.5% in the group assigned to undergo coronary-artery bypass grafting (CABG) and 55.8% in the group assigned to receive medical therapy (Panel A). Among patients with myocardial viability, the respective rates were 31.2% and 35.4% (Panel B). There was no significant interaction between viability status and treatment assignment with respect to mortality (P = 0.53) (Panel C).
N Engl J Med. N Engl J Med;364(17):1617-1625.
Publication Types
MeSH Terms
Secondary Source ID
Grant Support
Full Text Sources
Other Literature Sources
Medical